Mammoth Biosciences nabs $45M for CRISPR drugs, diagnostics work

CRISPR-Cas9
CRISPR (Ernesto del Aguila III, National Human Genome Research Institute, NIH)

Mammoth Biosciences has banked a $45 million second funding round as it looks to double down on its next-gen gene-editing tech.

Mammoth unveiled itself back in 2018 with technology licensed from the lab of Jennifer Doudna, Ph.D., and a mission to develop a CRISPR-based platform that can detect any biomarker containing DNA or RNA.

The endgame is a point-of-care diagnostic tool that can test for multiple conditions at once for use in hospitals and at home. Speaking to FierceBiotech during its official launch two years ago, the startup told us its first priority was building out the CRISPR platform, which includes creating some tests in-house.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

It was also looking for partners—today, the specifics are still under wraps, but it wants biopharma partners in the hope it can add “complementary skills to leverage these new proteins in gene-editing, therapeutic, and diagnostic applications to deliver on the promise of this ground-breaking CRISPR technology.”

The company did say its focus was diagnostics, which would be a whole new area for this tech, as well as searching out new therapies, with the $45 million series B set to be funneled into its CRISPR platform with a particular focus on the Mammoth-discovered and characterized Cas14.

Cas14 is an enzyme that “opens up new possibilities due to its extremely small size, diverse targeting ability and high-fidelity,” the biotech explained. This will help Mammoth hit on next-generation editing with a broader target range for both ex vivo and in vivo applications and is a foundation for enabling advanced CRISPR modalities such as targeted gene regulation, precision editing and beyond, it said.

The tech is still early-stage: CRISPR trials in humans are only just beginning, and its nascent potential also hinges on safety, as with any new tech. The promise, and the hype, is huge: While specific targets are not being discussed yet, gene editing could help treat a variety of diseases from rare genetics conditions to the likes of cancer.

“As a team on the frontlines of discovery in CRISPR, we’ve seen first-hand the need for new tools to deliver on the therapeutic and diagnostic promise that this technology has to offer,” explained Trevor Martin, CEO and co-founder of Mammoth Biosciences. “In powering new products in addition to diagnostics, we’re enabling the full potential of our platform to read and write the code of life and to fully transform how we interact with biology.”

Suggested Articles

The FDA granted new COVID-19 green lights to Fitbit’s emergency ventilator alternative, as well as to a second device designed by NASA engineers.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.